Upstream Bio, Inc.
NASDAQ:UPBBiotechnology
+$0.10 today
- Market cap
- $114.01M
- Beta
- 1.11
- P/E (TTM)
- -2.2
- EPS (TTM)
- -$2.89
Volume 1.24M
Average 0.66M
UPB Gross Profit
Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.
Upstream Bio, Inc.NASDAQ: UPB
Gross Profit · Q1 FY2026 · quarter ended Mar 2026
Gross profit growth accelerates
Q1 FY2026 gross profit of $985K rose 74.0% year over year, ahead of the +42.6% change in trailing-twelve-month gross profit. Sequentially, it rose 47.5% from the prior quarter. Over 3 fiscal years it compounded at +33.0% a year.
Context
- Gross profit amounted to 100.0% of revenue in FY2025, unchanged from a year earlier.
- Gross profit increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +74.0% holds above the trailing-twelve-month pace of +42.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Profit history
USD · from the income statement
- Latest · FY2025
- 2.85M USD
- Year-over-year change
- +20.4%
- 3-year CAGR
- +33.0%
| Period | Period end | Gross Profit | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.85M | +20.4% |
| FY2024 | 2024-12-31 | 2.37M | -0.4% |
| FY2023 | 2023-12-31 | 2.38M | +96.4% |
| FY2022 | 2022-12-31 | 1.21M | — |
Gross Profit vs competitors
How UPB compares with its peers on the latest reported figures
- Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +42.6% is the 6th highest of 10, against a peer median of +44.5%.
- Gross profit amounts to 98.5% of revenue for UPB, versus a peer median of 95.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $504.72M USD | -54.0% | +14.8% | 84.6% | |
| LTM Mar 2026 | $212.73M USD | +396.6% | — | 98.0% | |
| LTM Mar 2026 | $67.34M USD | -34.5% | +110.2% | 93.8% | |
| LTM Sep 2026 | $45.25M USD | +200.0% | — | 50.0% | |
UPBUpstream Bio, Inc. | LTM Mar 2026 | $3.27M USD | +42.6% | +33.0% | 98.5% |
| LTM Sep 2026 | -€106.45K EUR | -9.7% | — | — | |
| LTM Sep 2026 | -$108K USD | +99.7% | — | — | |
| LTM Jun 2026 | -$58.64M USD | +69.8% | — | 566.6% | |
| LTM Mar 2026 | -$101.61M USD | +44.5% | +5.1% | 153.7% | |
| LTM Mar 2026 | -$103.75M USD | -98.2% | — | — | |
| Peer median (excluding UPB) | — | +44.5% | +14.8% | 95.9% | |
Competitors are the stored peer set for UPB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 1.21M | 2.38M | 2.37M | 2.85M |
| Cost of Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | 1.21M | 2.38M | 2.37M | 2.85M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% |
| Research & Development | 18.66M | 31.8M | 62.97M | 136.81M |
| Selling, General & Admin | 6.46M | 10.7M | 17.17M | 26.41M |
| Operating Expenses | 25.12M | 42.49M | 80.13M | 163.22M |
| Depreciation & Amortization | 7K | 60K | 89K | 188K |
| EBITDA | (23.86M) | (20.48M) | (62.72M) | (143.26M) |
| EBITDA Margin | -1968.7% | -860.4% | -2646.3% | -5019.4% |
| Operating Income | (23.91M) | (40.11M) | (77.76M) | (160.36M) |
| Operating Margin | -1972.7% | -1685.5% | -3281.2% | -5618.8% |
| Interest Income | 205K | 4.17M | 12.12M | 16.93M |
| Interest Expense | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 41K | 19.58M | 14.96M | 16.92M |
| Income Before Tax | (23.87M) | (20.54M) | (62.81M) | (143.44M) |
| Pre-Tax Margin | -1969.3% | -862.9% | -2650.0% | -5026.0% |
| Income Tax Expense | 0 | 0 | 0 | 0 |
| Net Income | (23.87M) | (20.54M) | (62.81M) | (143.44M) |
| Net Margin | -1969.3% | -862.9% | -2650.0% | -5026.0% |
| EPS (Basic) | (0.66) | (1.05) | (1.49) | (2.66) |
| EPS (Diluted) | (0.66) | (1.05) | (1.49) | (2.66) |
| Weighted Avg Shares | 36.32M | 36.32M | 51.34M | 53.85M |
| Weighted Avg Shares (Diluted) | 36.32M | 36.32M | 51.34M | 53.85M |
Upstream Bio, Inc.
NASDAQ:UPB
Intrinsic Alpha fair value
Locked
Current Price
$2.08
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.